StockCIK 1649989
Outlook Therapeutics, Inc. (OTLK): Insider Trades and Fund Holdings
In the past 12 months, Outlook Therapeutics, Inc. insiders reported 3 open-market purchases worth $2.50M and 0 sales worth $0.
3Insider buys, 12 months
$2.50MBought by insiders, 12 months
$0Sold by insiders, 12 months
0Tracked funds holding
Recent insider trades
Open-market purchases (code P) and sales (code S) from Form 4. Grants, option exercises and gifts are not shown. Latest filing: Aug 14, 2026.
| Filed | Insider | Type | Value |
|---|---|---|---|
| Aug 14 | Ghiath M. SukhtianDirector | ▲ BUY | $2.50M |
| Aug 14 | Robert Charles JahrCEO | ▲ BUY | n/a |
| Aug 14 | Lawrence A. KenyonCFO | ▲ BUY | n/a |
Source: SEC Form 4 filings, retrieved Oct 28, 2026. How we read filings
Insiders who traded in the past year
| Insider | Role | Buys | Bought | Sells | Sold |
|---|---|---|---|---|---|
| Ghiath M. Sukhtian | Director | 1 | $2.50M | 0 | $0 |
| Robert Charles Jahr | CEO | 1 | $0 | 0 | $0 |
| Lawrence A. Kenyon | CFO | 1 | $0 | 0 | $0 |
ADVERTISEMENT
320 × 100 ad slot
Tracked funds that report OTLK
From each fund's latest 13F. Holdings are as of quarter end and are filed up to 45 days later.
| Fund | Shares | Value | Change |
|---|---|---|---|
| Renaissance Technologies | 0 | $0 | ▼ Sold out |
Source: SEC Form 13F-HR filings, retrieved Oct 28, 2026. How we read filings
Reading these numbers
Insiders sell for many reasons: taxes, diversification, a house. Purchases with their own money are rarer and are usually read as more informative. A Form 4 is due within two business days of the trade. How to read a Form 4 →